Yatin Suneja
Stock Analyst at Guggenheim
(2.10)
# 2,657
Out of 4,829 analysts
130
Total ratings
39.29%
Success rate
-7.96%
Average return
Main Sectors:
Stocks Rated by Yatin Suneja
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARGX argenx SE | Maintains: Buy | $1,100 → $1,065 | $549.27 | +93.89% | 10 | May 9, 2025 | |
| GHRS GH Research | Maintains: Buy | $32 → $29 | $10.38 | +179.38% | 1 | May 9, 2025 | |
| ANAB AnaptysBio | Maintains: Buy | $52 → $54 | $19.62 | +175.23% | 12 | May 6, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Buy | $155 → $165 | $115.71 | +42.60% | 5 | May 6, 2025 | |
| PHAT Phathom Pharmaceuticals | Maintains: Buy | $18 → $12 | $3.14 | +282.17% | 4 | May 2, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Buy | $940 → $810 | $527.78 | +53.47% | 6 | May 1, 2025 | |
| CABA Cabaletta Bio | Reiterates: Buy | $23 | $1.19 | +1,832.77% | 3 | Apr 1, 2025 | |
| ZURA Zura Bio | Reiterates: Buy | $15 | $1.21 | +1,139.67% | 2 | Mar 26, 2025 | |
| IFRX InflaRx | Maintains: Buy | $7 → $10 | $1.61 | +521.12% | 5 | Mar 26, 2025 | |
| LRMR Larimar Therapeutics | Reiterates: Buy | $26 | $2.12 | +1,126.42% | 4 | Mar 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $7 | $0.61 | +1,047.73% | 1 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | n/a | $14.02 | - | 8 | Mar 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $84 | $19.61 | +328.35% | 1 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $45 | $9.06 | +396.69% | 3 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.66 | - | 2 | Mar 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | n/a | $2.46 | - | 3 | Jan 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $45 | $8.35 | +438.92% | 3 | Jan 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $20 | $17.44 | +14.68% | 6 | Jan 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.55 | - | 2 | Dec 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | n/a | $15.10 | - | 2 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $50 → $65 | $14.10 | +360.99% | 1 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $155 → $170 | $38.35 | +343.29% | 2 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $32 | $5.03 | +536.18% | 1 | Jul 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.75 | - | 3 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $6.68 | +648.50% | 1 | Apr 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $72 → $90 | $18.33 | +391.00% | 5 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $110 → $125 | $107.76 | +16.00% | 8 | Feb 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $17 → $16 | $10.64 | +50.38% | 2 | Nov 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $70 → $77 | $38.39 | +100.60% | 3 | Nov 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.53 | - | 3 | Jul 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $49 | $35.02 | +39.92% | 2 | Jun 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $52 → $55 | $5.81 | +846.64% | 2 | May 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $270 → $350 | $118.17 | +196.18% | 3 | May 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $6.57 | - | 5 | Jan 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.42 | - | 3 | Oct 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $11.27 | +112.95% | 1 | May 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $29 → $34 | $63.32 | -46.30% | 2 | Jan 14, 2020 |
argenx SE
May 9, 2025
Maintains: Buy
Price Target: $1,100 → $1,065
Current: $549.27
Upside: +93.89%
GH Research
May 9, 2025
Maintains: Buy
Price Target: $32 → $29
Current: $10.38
Upside: +179.38%
AnaptysBio
May 6, 2025
Maintains: Buy
Price Target: $52 → $54
Current: $19.62
Upside: +175.23%
Neurocrine Biosciences
May 6, 2025
Maintains: Buy
Price Target: $155 → $165
Current: $115.71
Upside: +42.60%
Phathom Pharmaceuticals
May 2, 2025
Maintains: Buy
Price Target: $18 → $12
Current: $3.14
Upside: +282.17%
Regeneron Pharmaceuticals
May 1, 2025
Maintains: Buy
Price Target: $940 → $810
Current: $527.78
Upside: +53.47%
Cabaletta Bio
Apr 1, 2025
Reiterates: Buy
Price Target: $23
Current: $1.19
Upside: +1,832.77%
Zura Bio
Mar 26, 2025
Reiterates: Buy
Price Target: $15
Current: $1.21
Upside: +1,139.67%
InflaRx
Mar 26, 2025
Maintains: Buy
Price Target: $7 → $10
Current: $1.61
Upside: +521.12%
Larimar Therapeutics
Mar 25, 2025
Reiterates: Buy
Price Target: $26
Current: $2.12
Upside: +1,126.42%
Mar 21, 2025
Reiterates: Buy
Price Target: $7
Current: $0.61
Upside: +1,047.73%
Mar 20, 2025
Reiterates: Buy
Price Target: n/a
Current: $14.02
Upside: -
Mar 12, 2025
Reiterates: Buy
Price Target: $84
Current: $19.61
Upside: +328.35%
Mar 12, 2025
Reiterates: Buy
Price Target: $45
Current: $9.06
Upside: +396.69%
Mar 10, 2025
Downgrades: Neutral
Price Target: n/a
Current: $0.66
Upside: -
Jan 24, 2025
Reiterates: Buy
Price Target: n/a
Current: $2.46
Upside: -
Jan 3, 2025
Upgrades: Buy
Price Target: $45
Current: $8.35
Upside: +438.92%
Jan 3, 2025
Downgrades: Neutral
Price Target: $20
Current: $17.44
Upside: +14.68%
Dec 12, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.55
Upside: -
Dec 11, 2024
Reiterates: Buy
Price Target: n/a
Current: $15.10
Upside: -
Oct 25, 2024
Maintains: Buy
Price Target: $50 → $65
Current: $14.10
Upside: +360.99%
Aug 14, 2024
Maintains: Buy
Price Target: $155 → $170
Current: $38.35
Upside: +343.29%
Jul 23, 2024
Initiates: Buy
Price Target: $32
Current: $5.03
Upside: +536.18%
May 10, 2024
Downgrades: Neutral
Price Target: n/a
Current: $0.75
Upside: -
Apr 29, 2024
Initiates: Buy
Price Target: $50
Current: $6.68
Upside: +648.50%
Feb 27, 2024
Maintains: Buy
Price Target: $72 → $90
Current: $18.33
Upside: +391.00%
Feb 21, 2024
Maintains: Buy
Price Target: $110 → $125
Current: $107.76
Upside: +16.00%
Nov 15, 2023
Maintains: Buy
Price Target: $17 → $16
Current: $10.64
Upside: +50.38%
Nov 15, 2023
Maintains: Buy
Price Target: $70 → $77
Current: $38.39
Upside: +100.60%
Jul 17, 2023
Downgrades: Neutral
Price Target: n/a
Current: $1.53
Upside: -
Jun 15, 2023
Reiterates: Buy
Price Target: $49
Current: $35.02
Upside: +39.92%
May 18, 2023
Maintains: Buy
Price Target: $52 → $55
Current: $5.81
Upside: +846.64%
May 1, 2023
Upgrades: Buy
Price Target: $270 → $350
Current: $118.17
Upside: +196.18%
Jan 3, 2023
Downgrades: Neutral
Price Target: n/a
Current: $6.57
Upside: -
Oct 14, 2022
Downgrades: Neutral
Price Target: n/a
Current: $0.42
Upside: -
May 31, 2022
Initiates: Buy
Price Target: $24
Current: $11.27
Upside: +112.95%
Jan 14, 2020
Maintains: Buy
Price Target: $29 → $34
Current: $63.32
Upside: -46.30%